Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84568 trials found · Page 25 of 4229
-
Major trial tests new leukemia combo hoping to deepen remission
Disease control Recruiting nowThe purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
Direct brain artery treatment aims to stop stroke damage
Disease control Not yet recruitingThe ANGEL-MeVO-TNK is a multicentered, prospective, randomized, open label, blinded endpoint (PROBE) phase III trial. A total of 488 AIS patients (age ≥18 years) with acute MeVO-AIS (occlusion of the M2/M3, the A1/A2/A3, the P1/P2/P3, and with baseline NIHSS score \>5 or disablin…
Phase: PHASE3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Apr 22, 2026 11:28 UTC
-
Cancer treatment breakthrough: matching patients to therapies before surgery
Disease control Recruiting nowMost cancer treatments are developed without knowing whether the drug's targets are actually present in a patient's tumor or whether the patient is likely to benefit from the treatment. In addition, the immune environment surrounding the tumor changes significantly during the cou…
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Radiation 'Priming' tested to boost engineered immune cells against childhood cancers
Disease control Recruiting nowRAD3CAR is a phase I study designed to evaluatethe safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy. Primary objective: \- To evaluate the safety of B7-H3-CAR T cell therapy after priming with hypofractionated radiation ther…
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
New drug trial aims to stop deadly Cancer's return after surgery
Disease control Not yet recruitingThis study is a prospective, multicenter, multi-cohort Phase III clinical trial. It primarily enrolls high-risk recurrent esophageal cancer patients who have undergone R0 resection after neoadjuvant chemoimmunotherapy. Eligible patients are stratified based on pathological lymph …
Phase: PHASE3 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
New Triple-Threat therapy tested in major cervical cancer trial
Disease control Recruiting nowResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sa…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 14, 2026 13:10 UTC
-
New drug trial aims to halt debilitating nerve disease progression
Disease control Recruiting nowThe purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutri…
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Apr 17, 2026 16:12 UTC
-
New pill aims to stop lung Cancer's comeback after surgery
Disease control Recruiting nowThis study is open to adults 18 years and older who have early-stage non-small cell lung cancer (NSCLC). Their cancer must have a specific change in a gene called HER2. Genes provide the instructions for making proteins, and this change leads to a faulty HER2 protein. People can …
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Scientists re-engineer Patient's own cells to hunt deadly bone cancer
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of FH-FOLR1 ST chimeric antigen receptor (CAR) T cells and how well they work in treating patients with osteosarcoma that recurred or spread from where it first started to nearby tissue, lymph nodes, or distant part…
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
New pill aims to keep brain cancer at bay after standard treatment
Disease control Recruiting nowThe main goal of VIGOR is to demonstrate that vorasidenib maintenance therapy improves locally assessed progression-free survival (PFS) from enrolment compared to placebo in patients with IDH-mutant, CNS5 WHO Grade 2 or 3 astrocytoma following the completion of first-line chemora…
Phase: PHASE3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Apr 07, 2026 14:35 UTC
-
Scientists test 'Living Drug' for lupus patients who Don't respond to standard treatments
Disease control Recruiting nowThis study is a single arm, open, exploratory dose escalation clinical study to evaluate the safety, efficacy, and cellular metabolic dynamics of ct1195e cells in patients with SLE.
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Apr 22, 2026 11:28 UTC
-
New drug combo challenges standard care in major lung cancer trial
Disease control Not yet recruitingThis study is a randomized, controlled, double-blind, multicenter Phase III registration clinical trial, aiming to evaluate the efficacy and safety of HB0025 combined with chemotherapy (pemetrexed plus carboplatin/cisplatin) versus tislelizumab combined with chemotherapy (pemetre…
Phase: PHASE3 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 13, 2026 20:20 UTC
-
New study aims to make stem cell transplants safer for kids with leukemia
Disease control Not yet recruitingCurrent therapeutic strategies for high-risk or relapsed ALL patients often involve intensive treatments, including allogeneic hematopoietic stem cell transplantation (HSCT). HSCT remains a cornerstone of therapy, offering curative potential; however, it is associated with consid…
Phase: PHASE2, PHASE3 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated Apr 22, 2026 11:30 UTC
-
New combo therapy aims to give CLL patients a break from lifelong treatment
Disease control Not yet recruitingThis phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in a class of medications called B-cell lymp…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Apr 07, 2026 14:36 UTC
-
New lung cancer drug challenges standard treatment in major trial
Disease control Not yet recruitingThis study is a randomized, controlled, double-blind, multi-center phase III registration clinical trial, aiming to observe, compare and evaluate the efficacy and safety of HB0025 combined with paclitaxel + carboplatin compared with pembrolizumab combined with paclitaxel + carbop…
Phase: PHASE3 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 22, 2026 11:28 UTC
-
One-Shot eye injection could transform treatment for leading cause of blindness
Disease control Recruiting nowThis is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration. The study will evaluate a single subretinal injection of LX102 compared to …
Phase: PHASE3 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Global trial tests promising new drug against tough liver virus
Disease control Recruiting nowThis is a Phase 3, global, randomized, open-label, multicenter trial designed to evaluate the safety and efficacy of chronic treatment with brelovitug (BJT-778) for chronic hepatitis delta virus (HDV) infection. The objective of this study is to test the safety and effectiveness …
Phase: PHASE3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 22, 2026 11:28 UTC
-
New 'Triple-Target' immune cell therapy tested for tough blood cancers
Disease control Recruiting nowThis phase I trial tests the safety, side effects and best dose of anti-CD19/20/22 chimeric antigen receptor (CAR) T cells (TriCAR19.20.22 T cells) and how well they work in treating patients with non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL) and chronic lymphocytic le…
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC
-
Experimental cell therapy tested in kids with devastating immune diseases
Disease control Recruiting nowSafety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
Phase: PHASE1, PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
Half-Match transplant vs. strong drugs: new hope for bone marrow failure
Disease control Not yet recruitingThis study aims to compare the efficacy and safety of HLA-haploidentical hematopoietic stem cell transplantation (HLA-haplo HSCT) versus optimal immunosuppressive therapy (IST) as first-line treatments for severe aplastic anemia (SAA) through a real-world cohort design. The selec…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 06, 2026 14:14 UTC